Thus, we decided to investigate the potential of systemic and endovascular local lenvatinib delivery to halt aneurysm growth in experimental murine models, primary human AAA patient-derived cells, and a novel preclinical Yucatan LDLR–/– minipig AAA model. This evidence concerns the gene LDLR and triple-A syndrome.